NetworkNewsBreaks – PDS Biotechnology Corporation (NASDAQ: PDSB) Announces Q1 2020 Financial Results, Provides Business Update

May 15, 2020 11:57:55

PDS Biotechnology (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune(R) T-cell activating technology, on Wednesday announced its financial results for the first quarter ended March 31, 2020 and provided a business update. Among the highlights, the Company announced initiation of novel vaccine development programs for COVID-19 and universal influenza. “We have continued to leverage the versatility and potency of our Versamune(R) platform, as we expand our development program to include vaccines to protect against infectious diseases such as COVID-19 and influenza,” PDS Biotech President and CEO, Dr. Frank Bedu-Addo, stated in the news release. “We believe that Versamune’s(R) ability to induce a superior range of protective immune responses – including neutralizing antibodies, killer T-cells and memory T-cells – uniquely positions PDS to develop more effective vaccines to provide long-term protection against the spread of  agents with pandemic potential. We have recently initiated pre-clinical testing for our COVID-19 vaccine candidates and are in active discussions with both government agencies and NGOs to determine the most expeditious path forward.”

To view the full press release, visit

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune(R) T-cell activating technology platform. Versamune(R) effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune(R) and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.